{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T01:15:05Z","timestamp":1795050905380,"version":"4.10.2"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"<jats:sec id=\"ab-eoi220068-4\"><jats:title>Importance<\/jats:title><jats:p>Age-related macular degeneration (AMD) is a leading cause of vision loss and blindness. AMD prevalence has not been estimated for the US in over a decade and early-stage AMD prevalence estimates are scarce and inconsistently measured.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220068-5\"><jats:title>Objective<\/jats:title><jats:p>To produce estimates of early- and late-stage AMD prevalence overall and by age, gender, race and ethnicity, county, and state.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220068-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>The study team conducted a bayesian meta-regression analysis of relevant data sources containing information on the prevalence of AMD among different population groups in the US.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220068-7\"><jats:title>Data Sources<\/jats:title><jats:p>We included data from the American Community Survey (2019), the National Health and Nutrition Examination Survey (2005-2008), US Centers for Medicare &amp;amp;amp; Medicaid Services claims for fee-for-service beneficiaries (2018), and population-based studies (2004-2016).<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220068-8\"><jats:title>Study Selection<\/jats:title><jats:p>We included all relevant data from the US Centers for Disease Control and Prevention\u2019s Vision and Eye Health Surveillance System.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220068-9\"><jats:title>Data Extraction and Synthesis<\/jats:title><jats:p>The prevalence of early- and late-stage AMD was estimated and stratified when possible by factors including county, age group, gender, and race and ethnicity. Data analysis occurred from June 2021 to April 2022.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220068-10\"><jats:title>Main Outcomes or Measures<\/jats:title><jats:p>The prevalence of early- (defined as retinal pigment epithelium abnormalities or the presence of drusen 125 or more microns in diameter in either eye) and late-stage (defined as choroidal neovascularization and\/or geographic atrophy in either eye) manifestations of AMD.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220068-11\"><jats:title>Results<\/jats:title><jats:p>This study used data from nationally representative and local population-based studies that represent the populations in which they were conducted. For 2019, we estimated that there were 18.34 million people 40 years and older (95% uncertainty interval [UI], 15.30-22.03) living with early-stage AMD, corresponding to a crude prevalence rate of 11.64% (95% UI, 9.71-13.98). We estimated there were 1.49 million people 40 years and older (95% UI, 0.97-2.15) living with late-stage AMD, corresponding to a crude prevalence rate of 0.94% (95% UI, 0.62-1.36). Prevalence rates of early- and late-stage AMD varied by demographic characteristics and geography.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220068-12\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>We estimated a higher prevalence of early-stage AMD and a similar prevalence of late-stage AMD as compared with earlier studies. State-level and county-level AMD estimates may help guide public health practice.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2022.4401","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T15:33:03Z","timestamp":1667489583000},"page":"1202","source":"Crossref","is-referenced-by-count":286,"title":["Prevalence of Age-Related Macular Degeneration in the US in 2019"],"prefix":"10.1001","volume":"140","author":[{"given":"David B.","family":"Rein","sequence":"first","affiliation":[{"name":"NORC, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S","family":"Wittenborn","sequence":"additional","affiliation":[{"name":"NORC, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeb","family":"Burke-Conte","sequence":"additional","affiliation":[{"name":"Institute for Health Metrics and Evaluation, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Gulia","sequence":"additional","affiliation":[{"name":"Institute for Health Metrics and Evaluation, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshana","family":"Robalik","sequence":"additional","affiliation":[{"name":"Institute for Health Metrics and Evaluation, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua R.","family":"Ehrlich","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor"},{"name":"Institute for Social Research, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Lundeen","sequence":"additional","affiliation":[{"name":"Vision Health Initiative, Division of Diabetes Translation, US Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham D.","family":"Flaxman","sequence":"additional","affiliation":[{"name":"Institute for Health Metrics and Evaluation, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"eoi220068r1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.122.4.477","article-title":"Causes and prevalence of visual impairment among adults in the United States.","volume":"122","author":"Congdon","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"eoi220068r2","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","article-title":"Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to sight: an analysis for the Global Burden of Disease Study.","volume":"9","author":"GBD 2019 Blindness and Vision Impairment Collaborators","year":"2021","journal-title":"Lancet Glob Health"},{"issue":"1","key":"eoi220068r3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ophtha.2019.09.024","article-title":"Age-related macular degeneration preferred practice pattern.","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"key":"eoi220068r4","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.58","article-title":"Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments.","author":"Rein","year":"2009","journal-title":"Arch Ophthalmol"},{"issue":"20","key":"eoi220068r6","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1001\/jama.2009.729","article-title":"Forecasting age-related macular degeneration through 2050.","volume":"301","author":"Klein","year":"2009","journal-title":"JAMA"},{"issue":"9","key":"eoi220068r7","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.ophtha.2008.01.026","article-title":"Age-period-cohort effect on the incidence of age-related macular degeneration: the Beaver Dam Eye Study.","volume":"115","author":"Klein","year":"2008","journal-title":"Ophthalmology"},{"issue":"134","key":"eoi220068r10","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/jamaophthalmol.2016.1261","article-title":"Prevalence and causes of visual impairment and blindness in Chinese American adults: the Chinese American eye study.","author":"Varma","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"eoi220068r11","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.ophtha.2004.02.002","article-title":"Prevalence and risk indicators of visual impairment and blindness in Latinos: the Los Angeles Latino Eye Study.","volume":"111","author":"Varma","year":"2004","journal-title":"Ophthalmology"},{"issue":"11","key":"eoi220068r12","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1001\/archopht.123.11.1575","article-title":"Prevalence of age-related macular degeneration in a population-based sample of Hispanic people in Arizona: Proyecto VER.","volume":"123","author":"Mu\u00f1oz","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"22","key":"eoi220068r13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/archopht.123.11.1575","article-title":"Visual impairment in White, Chinese, Black, and Hispanic participants from the multi-ethnic study of atherosclerosis cohort.","author":"Fisher","year":"2015","journal-title":"Ophthalmic Epidemiol"},{"issue":"4","key":"eoi220068r14","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","article-title":"Clinical classification of age-related macular degeneration.","volume":"120","author":"Ferris","year":"2013","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi220068r18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1001\/archophthalmol.2010.318","article-title":"Prevalence of age-related macular degeneration in the US population.","volume":"129","author":"Klein","year":"2011","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"eoi220068r21","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1001\/archopht.122.4.564","article-title":"Prevalence of age-related macular degeneration in the United States.","volume":"122","author":"Friedman","year":"2004","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"eoi220068r22","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ophtha.2011.09.027","article-title":"Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis.","volume":"119","author":"Rudnicka","year":"2012","journal-title":"Ophthalmology"},{"issue":"10","key":"eoi220068r23","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/archopht.119.10.1417","article-title":"A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.","volume":"119","author":"Age Related Eye Disease Study Research Group","year":"2001","journal-title":"Arch Ophthalmology"},{"issue":"10","key":"eoi220068r25","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.2337\/diacare.28.10.2448","article-title":"The influence of age, duration of diabetes, cataract, and pupil size on image quality in digital photographic retinal screening.","volume":"28","author":"Scanlon","year":"2005","journal-title":"Diabetes Care"},{"issue":"6","key":"eoi220068r26","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.ophtha.2016.01.043","article-title":"Identification of diabetic retinopathy and ungradable image rate with ultrawide field imaging in a national teleophthalmology program.","volume":"123","author":"Silva","year":"2016","journal-title":"Ophthalmology"},{"key":"eoi220068r5","first-page":"1","volume-title":"The prevalence of diagnosis of major eye diseases and their associated payments in the Medicare fee-for-service program. Ophthalmic Epidemiology","author":"Wittenborn","year":"2021"},{"key":"eoi220068r9","volume-title":"An Integrative Metaregression Framework for Descriptive Epidemiology","author":"Flaxman","year":"2015"},{"key":"eoi220068r15","first-page":"1","volume-title":"Trimmed Constrained Mixed Effects Models: Formulations and Algorithms","author":"Zheng","year":"2021"},{"key":"eoi220068r8","unstructured":"Centers for Disease Control and Prevention. The Vision and Eye Health Surveillance System (VEHSS). Accessed October 3, 2022. https:\/\/www.cdc.gov\/visionhealth\/vehss\/index.html"},{"key":"eoi220068r16","unstructured":"Centers for Medicare & Medicaid Services. MA [Medicare Advantage] state\/county penetration 2018 06. Accessed October 3, 2022. https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/MCRAdvPartDEnrolData\/MA-State-County-Penetration-Items\/MA-State-County-Penetration-2018-06"},{"key":"eoi220068r17","unstructured":"Health Services Resources Administration. Area health resources files. Accessed October 3, 2022. https:\/\/data.hrsa.gov\/topics\/health-workforce\/ahrf Accessed 11\/29"},{"key":"eoi220068r19","unstructured":"Kaiser Family Foundation. Distribution of Medicare beneficiaries by eligibility category. Accessed October 3, 2022. https:\/\/www.kff.org\/medicare\/state-indicator\/distribution-of-medicare-beneficiaries-by-eligibility-category-2\/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D"},{"key":"eoi220068r20","unstructured":"US Census Bureau. American Community Survey (ACS). Accessed October 3, 2022. https:\/\/www.census.gov\/programs-surveys\/acs Accessed 10\/3"},{"key":"eoi220068r24","unstructured":"US Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. 2007-2008 data documentation, codebook, and frequencies: Accessed October 3, 2022. https:\/\/wwwn.cdc.gov\/Nchs\/Nhanes\/2007-2008\/VIX_E.html"},{"key":"eoi220068r27","unstructured":"US Centers for Disease Control and Prevention. Vision and Eye Health Surveillance System (VEHSS). Accessed October 3, 2022. https:\/\/www.cdc.gov\/visionhealth\/vehss\/"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2797921\/jamaophthalmology_rein_2022_oi_220068_1670963675.41862.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T16:05:17Z","timestamp":1671120317000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2797921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.4401","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}